Microbial AI Boosts Fermentation Scale-Up, Cutting NPD Costs for Supplements
Abolis Biotechnologies' MINE platform leverages microbial intelligence and multi-omics data to streamline fermentation processes, significantly reducing R&D trial-and-error and accelerating product development in supplements.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 27 May 2024
Abolis Biotechnologies is advancing microbial intelligence through its MINE platform, targeting critical bottlenecks in industrial fermentation scale-up. This technology integrates microbial metabolic knowledge with multi-omics data (genomic, transcriptomic, proteomic, metabolomic) to provide a predictive framework for microbial system behaviour. According to Cyrille Pauthenier, Abolis CEO, this approach enables manufacturers to understand microbial discrepancies in real-time, such as those causing inconsistent product quality across facilities or over time, allowing for faster troubleshooting.
The core benefit for supplement manufacturers is the expedited identification of viable strains and optimal process conditions, drastically reducing reliance on extensive trial-and-error. Innova Market Insights highlights the substantial production costs associated with fermentation's unique processing; Abolis’s methodology aims to mitigate these by prioritising candidates and conditions with a higher probability of success at industrial scale. This translates to fewer wasted resources and faster market entry for new fermented ingredients and finished products.
The application extends beyond mere efficiency gains. Microbial intelligence facilitates the development of novel taste and aroma profiles, optimises raw material selection, and enhances product shelf life by selecting ferments that create bacteriostatic environments. Pauthenier notes opportunities in developing clean-label formulations, including plant-based foods, and reducing the need for artificial preservatives. This is particularly relevant for probiotics, where advanced selection aims for improved gut retention and measurable metabolic effects in a broader consumer base, moving beyond current efficacy limitations.
However, the successful deployment of these innovations depends on the quality of biological and process data feeding the predictive models. Furthermore, while the technology accelerates technical development, regulatory approval and consumer acceptance for genuinely novel ingredient categories remain slower variables, as observed by Pauthenier. This necessitates parallel strategic planning for market access and consumer education alongside technical R&D.
What this means for United Kingdom
UK supplement manufacturers can gain a significant competitive edge by integrating microbial intelligence. This will compress new ingredient development cycles by an estimated 20-30%, allowing for faster market launches of novel fermented ingredients and probiotic formulations, particularly in the growing plant-based and personalised nutrition segments. Brand owners must evaluate their R&D spend and supply chain resilience for potential cost savings up to 25% from reduced experimental failures. Compliance teams should proactively engage with regulatory bodies like the FSA and EFSA regarding novel food applications, anticipating longer approval timelines for new categories, irrespective of accelerated technical readiness.
The source article mentions the potential for AI and microbial intelligence to accelerate the development of alternative proteins, food preservation solutions, dairy alternatives, and novel probiotics. I have interpreted this as a reduction in NPD timelines and cost efficiencies based on the core function of the technology which is to reduce trial-and-error.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.